| ADC | Antibody Drug Coniugated |
| BC | Breast Cancer |
| BL1/2 | Basal-Like 1/2 |
| BRCA1/2 | BReast CAncer type 1 and Type 2 |
| CSCs | Cancer Stem Cells |
| CTCs | Circulating Tumor Cells |
| dMMR | Mismatch Repair deficiency |
| DSBs | DNA Double Strand Breaks |
| DCs | Dendritic Cells |
| DFS | Disease Free Survival |
| EMT | Epithelial Mesenchymal Transition |
| ER | Estrogen Receptor |
| FDA | Food and Drug Administration |
| FFPE | Formalin-fixed paraffin embedded |
| GEP | Gene Expression Profile |
| gBRCAm | germline BRCA mutations |
| GPNMB | Glycoprotein non-metastatic b |
| HBOC | Hereditary Breast and Ovarian Cancer Syndrome |
| HRD | Homologous Recombination Deficiency |
| HRD-LOD | HRD-Loss of Heterozygosity |
| HRD-LST | HDR-Large Scale Transition |
| HRD-TAI | HDR-Telomeric Allelic Imbalance |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| HR | Homologous Recombination |
| HRR | Homologous Recombination Repair |
| IC | Immune Cells |
| ICI | Immune Checkpoint Inhibitor |
| IM | Immunomodulatory |
| LAG3 | Lymphocyte-associated gene 3 |
| LAR | Luminal Androgen Receptor |
| MAP | Mitogen-Activated Protein |
| MBC | Metastatic Breast Cancer |
| MHC | Major Histocompatibility Complex |
| MMAE | Microtubule-disrupting agent monomethyl auristatin E |
| MMR | Mismatch Repair |
| MSI | Microsatellite Instability |
| MSI-H | High Microsatellite Instability |
| MSL | Mesenchymal Stem-Like |
| mTOR | Mammalian Target Of Rapamycin |
| mTORC1 | mTOR complex 1 |
| NGS | Next Generation Sequencing |
| NHEJ | Non-Homologous End Joining |
| NK | Natural Killer |
| ORR | Objective Response Rate |
| OS | Overall Survival |
| OXPHOS | Oxidative Phosphorylation |
| pCR | Pathological Complete Response |
| PARP | Poly ADP-ribose polymerase |
| PARPi | Poly ADP-ribose polymerase Inhibitors |
| PD-1 | Programmed Cell Death-1 |
| PD-L1 | Programmed Cell Death Ligand-1 |
| PDX | Patient-Derived-Xenograft |
| PFS | Progression Free Survival |
| PI3K | Phosphatidylinositol 3-kinase |
| PIK3CA | Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit, alpha |
| PIP3 | Phosphatidylinositol (3,4,5)-trisphosphate |
| PTEN | Phosphatase and Tensin Homolog |
| PR | Progesterone Receptor |
| RCB | Residual Cancer Burden |
| sBRCAm | Somatic BRCA mutations |
| TC | Tumor Cells |
| TIL | Tumor Infiltrating Lymphocytes |
| TMB | Tumor Mutational Burden |
| TNBC | Triple Negative Breast Cancer |
| UNS | Unstable |